We develop novel and differentiated oral small molecule therapies for patients suffering from diseases with significant unmet medical need
We are a late-stage clinical biopharmaceutical company dedicated to the development of oral therapies for the treatment of patients with significant unmet medical needs.
Our activities are currently focused on the development of lanifibranor, a next-generation drug candidate being evaluated in the pivotal Phase 3 NATiV3 trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis.
Leveraging our scientific and clinical expertise in metabolic diseases and fibrosis, we are focused on generating robust clinical data and preparing the next stages of development, with the ambition of bringing a new therapeutic option to patients.
Research Areas & Pipeline
We develop novel and differentiated oral small molecule therapies for patients suffering from diseases with significant unmet medical need.
Lanifibranor, our lead product candidate, is an anti-fibrotic treatment acting on the three PPARs (peroxisome proliferator-activated receptors), which plays a key role in controlling the metabolic, inflammatory and fibrotic processes. We are investigating lanifibranor for the treatment of NASH/MASH, a severe and increasingly prevalent liver disease that is already affecting over 30 million people in the United States.
